These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 29193711)

  • 1. Early improvement predicts 8-week treatment outcome in patients with generalized anxiety disorder treated with escitalopram or venlafaxine.
    Qian M; Shen Z; Lin M; Guan T; Yang J; Li L; Shen X; Yuan Y
    Asia Pac Psychiatry; 2017 Dec; 9(4):. PubMed ID: 29193711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders: Association With Treatment Outcomes.
    Altmann H; Stahl ST; Gebara MA; Lenze EJ; Mulsant BH; Blumberger DM; Reynolds CF; Karp JF
    J Clin Psychiatry; 2020 Sep; 81(6):. PubMed ID: 32991792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A; Korotzer A; Gommoll C; Li D
    Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher baseline serum adiponectin predicts better treatment remission in patients with generalized anxiety disorder treated with escitalopram.
    Shen Z; Wang F; Cui L; Ren L; Hong X; Yuan Y; Shen X
    Ann Palliat Med; 2021 Jul; 10(7):7634-7643. PubMed ID: 34353051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance.
    Fabbri C; Crisafulli C; Calati R; Albani D; Forloni G; Calabrò M; Martines R; Kasper S; Zohar J; Juven-Wetzler A; Souery D; Montgomery S; Mendlewicz J; Serretti A
    Eur Arch Psychiatry Clin Neurosci; 2017 Dec; 267(8):723-735. PubMed ID: 28260126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.
    Rickels K; Pollack MH; Sheehan DV; Haskins JT
    Am J Psychiatry; 2000 Jun; 157(6):968-74. PubMed ID: 10831478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EEG Abnormalities Are Associated With Poorer Depressive Symptom Outcomes With Escitalopram and Venlafaxine-XR, but Not Sertraline: Results From the Multicenter Randomized iSPOT-D Study.
    Arns M; Gordon E; Boutros NN
    Clin EEG Neurosci; 2017 Jan; 48(1):33-40. PubMed ID: 26674366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remission of generalized anxiety disorder after 6 months of open-label treatment with venlafaxine XR.
    Rickels K; Etemad B; Rynn MA; Lohoff FW; Mandos LA; Gallop R
    Psychother Psychosom; 2013; 82(6):363-71. PubMed ID: 24061331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Escitalopram: a review of its use in the management of anxiety disorders.
    Dhillon S; Scott LJ; Plosker GL
    CNS Drugs; 2006; 20(9):763-90. PubMed ID: 16953656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?
    Baldwin DS; Schweizer E; Xu Y; Lyndon G
    Eur Neuropsychopharmacol; 2012 Feb; 22(2):137-42. PubMed ID: 21839620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation symptoms in depression and anxiety disorders.
    Baldwin DS; Montgomery SA; Nil R; Lader M
    Int J Neuropsychopharmacol; 2007 Feb; 10(1):73-84. PubMed ID: 16359583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of NPSR1 rs324981 polymorphism and treatment response to antidepressants in Chinese Han population with generalized anxiety disorder.
    He Q; Shen Z; Ren L; Wang X; Qian M; Zhu J; Shen X
    Biochem Biophys Res Commun; 2018 Sep; 504(1):137-142. PubMed ID: 30190127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid major depression or dysthymia: effectiveness, tolerability and predictors of response.
    Perugi G; Frare F; Toni C; Ruffolo G; Torti C
    Neuropsychobiology; 2002; 46(3):145-9. PubMed ID: 12422062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term efficacy and tolerability of venlafaxine extended release in adults with generalized anxiety disorder without depression: A meta-analysis.
    Li X; Zhu L; Su Y; Fang S
    PLoS One; 2017; 12(10):e0185865. PubMed ID: 28982121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder.
    Bystritsky A; Kerwin L; Feusner JD; Vapnik T
    Psychopharmacol Bull; 2008; 41(1):46-51. PubMed ID: 18362870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The roles of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) in predicting treatment remission in a Chinese Han population with generalized anxiety disorder.
    Shen Z; Zhu J; Yuan Y; Ren L; Qian M; Lin M; Cai M; Zhang Z; Shen X
    Psychiatry Res; 2019 Jan; 271():319-324. PubMed ID: 30529313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder.
    Montgomery SA; Huusom AK; Bothmer J
    Neuropsychobiology; 2004; 50(1):57-64. PubMed ID: 15179022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression--The EMC trial.
    Tadić A; Wachtlin D; Berger M; Braus DF; van Calker D; Dahmen N; Dreimüller N; Engel A; Gorbulev S; Helmreich I; Kaiser AK; Kronfeld K; Schlicht KF; Tüscher O; Wagner S; Hiemke C; Lieb K
    Eur Neuropsychopharmacol; 2016 Apr; 26(4):705-16. PubMed ID: 26899588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study.
    Allgulander C; Hackett D; Salinas E
    Br J Psychiatry; 2001 Jul; 179():15-22. PubMed ID: 11435263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada.
    Iskedjian M; Walker JH; Bereza BG; Le Melledo JM; Einarson TR
    Curr Med Res Opin; 2008 May; 24(5):1539-48. PubMed ID: 18416886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.